BLTEBelite Bio, Inc

$7B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$7M

Net Income

-$7M

EPS (Diluted)

$-0.25

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

$0

Free Cash Flow

$0

Stock-Based Comp.

$3,823

Balance Sheet

Total Assets

$95M

Total Liabilities

$4M

Stockholders' Equity

$90M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$7M	-$7M	-3.5%
Net Income	-$7M	-$7M	-3.0%

BLTE Q4 2023 Earnings — Belite Bio, Inc Revenue & Financial Results | Market Cap Arena